Explore our comprehensive portfolio that addresses the complete care continuum for many of the world’s most threatening diseases. 

Discover the stories of pioneers pushing the boundaries of what’s possible in healthcare to help improve people’s lives around the world.

Patient-centered innovation has been and always will be at the core of our company. Dive deeper into our fascinating technologies.

We pioneer breakthroughs in healthcare. For everyone. Everywhere. Sustainably. Learn more about our purpose, our innovation leadership, our culture, and our strategy.

  1. Home

  2. Press center
  3. Press releases
  4. Siemens Healthineers continues to post strong growth – outlook raised again
Press release

Siemens Healthineers continues to post strong growth – outlook raised again

Published on May 3, 2021

Siemens Healthineers AG today announced its results for the second quarter of fiscal year 2021 that ended March 31, 2021.


Q2 Fiscal Year 2021

  • Very good revenue development continued in the second quarter with 12.9% comparable growth from the prior-year quarter
  • Equipment book-to-bill ratio at 1.08
  • Development in Diagnostics again outstanding with 29.1% comparable revenue growth – continued high demand for rapid COVID-19 antigen tests
  • Strong comparable revenue growth of 7.4% in Imaging; Advanced Therapies with comparable growth of 2.0%
  • Adjusted EBIT margin at 16.8%
  • Adjusted basic earnings per share at €0.44
  • Free cash flow of €359 million significantly above comparatively weak prior-year figure

Updated Outlook for Fiscal Year 2021

  • Varian acquisition successfully completed on April 15, 2021
  • Comparable revenue growth between 14% and 17% expected (previously 8% to 12%)
  • Adjusted basic earnings per share between €1.90 and €2.05 (previously €1.63 to €1.82)

Bernd Montag, CEO of Siemens Healthineers AG:
 »The Siemens Healthineers team has done an outstanding job during the past months. While we have further improved our operational performance and have once again made a valuable contribution to cope with this historical crisis, we have at the same time managed to successfully complete the largest transaction in our history. Together with Varian, we are making a leap in cancer care and a leap in our impact on global healthcare. With our even more comprehensive portfolio, we are addressing many of the most important diseases. Against the backdrop of continued strong business development in the second quarter and the transformative merger with Varian, we have again raised our outlook for the current fiscal year.«

Download quarterly statement(pdf, 343.98 KB)

- Siemens Healthineers 2021 -

Siemens Healthineers AG (listed in Frankfurt, Germany: SHL) is shaping the future of healthcare. As a leading medical technology company headquartered in Erlangen, Germany, Siemens Healthineers enables healthcare providers worldwide through its regional companies to increase value by empowering them on their journey towards expanding precision medicine, transforming care delivery, improving the patient experience, and digitalizing healthcare. Siemens Healthineers is continuously developing its product and service portfolio, with AI-supported applications and digital offerings that play an increasingly important role in the next generation of medical technology. These new applications will enhance the company’s foundation in in-vitro diagnostics, image-guided therapy, in-vivo diagnostics, and innovative cancer care. Siemens Healthineers also provides a range of services and solutions to enhance healthcare providers’ ability to provide high-quality, efficient care to patients. In fiscal 2020, which ended on September 30, 2020, Siemens Healthineers generated revenue of €14.5 billion and adjusted EBIT of €2.2 billion. Following the acquisition of Varian Medical Systems, Inc. the company has approximately 65,000 employees worldwide.